All In Biotech

Drug Trial Radar · NCT02702180

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

A Randomised, Double-blind, Placebo-controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients

Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 139 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

139

Actual

Start

Mar 21, 2016

Primary completion

Apr 19, 2019

Study completion Sep 27, 2019

Sponsor

Lead sponsor
Savara Inc.Industry
Sponsor type
Industry
First posted
Mar 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates inhaled molgramostim (recombinant human granulocyte macrophage-colony stimulating factor \[rhGM-CSF\]) in the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) patients. A third of the patients will receive inhaled molgramostim once daily for 24 weeks, a third will receive inhaled molgramostim intermittently (7 days on, 7 days off) for 24 weeks and a third will receive inhaled matching placebo for 24 weeks.

Conditions

  • Autoimmune Pulmonary Alveolar Proteinosis

Interventions

  • MolgramostimDrug

    300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation

  • PlaceboDrug

    Placebo nebulizer solution for inhalation

  • PARI eFlow nebulizer systemDevice

    PARI eFlow nebulizer system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline of Alveolar-arterial Oxygen Concentration (A-a(DO2)) After 24 Weeks of TreatmentTime frame: From baseline to 24 weeks

Locations

30 sites in 18 countries. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California

  • University of Florida

    Gainesville, Florida

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, Australia

  • Aarhus University Hospital

    Aarhus, Denmark

  • CHU Rennes Hospital Pontchaillou

    Rennes, France

  • Westdeutsches Lungenzentrum am Universitätsklinikum Essen

    Essen, Germany

  • Asklepios Fachkliniken München - Gauting

    Gauting, Germany

  • Thoraxklinik am Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Universitätsklinikum Schleswig-Holstein Zentralklinikum, Lübeck Medizinische Klinik III, Pneumologie

    Lübeck, Germany

  • Attikon University Hospital

    Athens, Greece

  • Rabin Medical Center

    Petah Tikva, Israel

  • IRCCS Policlinico San Matteo

    Pavia, Italy

  • Niigata University Medical and Dental Hospital

    Niigata, Japan

  • National Hospital Organization Kinki-Chuo

    Osaka, Japan

  • Tohoku University Hospital

    Sendai, Japan

  • Aichi Medical University Hospital

    Toyohashi, Japan

  • Kanagawa Cardiovascular and Respiratory Center

    Yokohama, Japan

  • St. Antonius Hospital

    Nieuwegein, Netherlands

  • Hospital de dia de Pneumologia

    Lisbon, Portugal

  • Hospital Sao Joao

    Porto, Portugal

  • City Hospital St. Petersburg

    Saint Petersburg, Russia

  • II. Pulmonary Department National Institut for TB, Lung Diseases and Chest Surgery

    Vyšné Hágy, Slovakia

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center, Division of Pulmonary and Critical Care Medicine

    Seoul, South Korea

  • Samsung Medical Center, Division of Pulmonary and Critical Care Medicine

    Seoul, South Korea

  • Hospital University de Bellvitge (HUB)

    Barcelona, Spain

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Switzerland

  • Yedikule Pulmonary Diseases and Pulmonary Surgery Training and Research Hospital

    Istanbul, Turkey (Türkiye)

  • Royal Brompton Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.